×
About 20,875 results

ALLMedicine™ Neutropenia Center

Research & Reviews  6,184 results

Levofloxacin prophylaxis for pediatric leukemia patients: Longitudinal follow-up for im...
https://doi.org/10.1002/pbc.29525
Pediatric Blood & Cancer; Davis A, Stevens AM et. al.

Jan 15th, 2022 - Bloodstream infections (BSIs) cause morbidity and mortality in pediatric patients with leukemia. Antibiotic prophylaxis during periods of chemotherapy-induced neutropenia may reduce the incidence of BSIs. A levofloxacin prophylaxis guideline was i...

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-nega...
https://doi.org/10.1016/S1470-2045(21)00692-6
The Lancet. Oncology; Kang YK, Chen LT et. al.

Jan 15th, 2022 - The additive or synergistic sustained antitumour effect of immune checkpoint inhibitors in combination with oxaliplatin-based chemotherapy has previously been reported. We investigated the efficacy of nivolumab plus oxaliplatin-based chemotherapy ...

Prophylactic administration of mecapegfilgrastim after chemotherapy in patients with ly...
https://doi.org/10.21037/apm-21-3209
Annals of Palliative Medicine; Zheng M, Wen X et. al.

Jan 13th, 2022 - Neutropenia is a common and serious complication encountered during chemotherapy treatment of cancer patients. The incidence of neutropenia increases the risk of infection and can influence the chemotherapy treatment in terms of drug dosage and tr...

Oral vancomycin for clostridioides difficile prophylaxis in allogenic hematopoietic cel...
https://doi.org/10.1111/tid.13790
Transplant Infectious Disease : an Official Journal of Th... Altemeier OJ, Konrardy KT

Jan 12th, 2022 - Neutropenia and antibiotic use put patients at risk for Clostridioides difficile infection (CDI) following allogenic hematopoietic cell transplant (alloHCT). CDI following alloHCT has been associated with acute graft versus host disease (aGVHD), a...

see more →

Guidelines  15 results

Emerging challenges in the evaluation of fever in cancer patients at risk of febrile ne...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682766
Supportive Care in Cancer : Official Journal of the Multi... Cooksley T, Font C et. al.

Nov 25th, 2020 - Patients with cancer are at higher risk of more severe COVID-19 infection and have more associated complications. The position paper describes the management of cancer patients, especially those receiving anticancer treatment, during the COVID-19 ...

Management and Appropriate Use of Diazoxide in Infants and Children with Hyperinsulinism.
https://doi.org/10.1210/clinem/dgaa543
The Journal of Clinical Endocrinology and Metabolism; Brar PC, Heksch R et. al.

Aug 19th, 2020 - The diagnosis of hypoglycemia and the use of diazoxide have risen in the last decade. Diazoxide is the only Food and Drug Agency-approved pharmacologic treatment for neonatal hypoglycemia caused by hyperinsulinism (HI). Recent publications have hi...

ACR Appropriateness Criteria® Acute Nonlocalized Abdominal Pain.
https://doi.org/10.1016/j.jacr.2018.09.010
Journal of the American College of Radiology : JACR; , Scheirey CD et. al.

Nov 6th, 2018 - The range of pathology in adults that can produce abdominal pain is broad and necessitates an imaging approach to evaluate many different organ systems. Although localizing pain prompts directed imaging/management, clinical presentations may vary ...

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASC...
https://doi.org/10.1200/JCO.18.00374
Journal of Clinical Oncology : Official Journal of the Am... Taplitz RA, Kennedy EB et. al.

Sep 5th, 2018 - To provide an updated joint ASCO/Infectious Diseases Society of America (IDSA) guideline on antimicrobial prophylaxis for adult patients with immunosuppression associated with cancer and its treatment. ASCO and IDSA convened an update Expert Panel...

Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: Americ...
https://doi.org/10.1200/JCO.2017.77.6211
Journal of Clinical Oncology : Official Journal of the Am... Taplitz RA, Kennedy EB et. al.

Feb 21st, 2018 - Purpose To provide an updated joint ASCO/Infectious Diseases Society of American (IDSA) guideline on outpatient management of fever and neutropenia in patients with cancer. Methods ASCO and IDSA convened an Update Expert Panel and conducted a syst...

see more →

Drugs  248 results see all →

Clinicaltrials.gov  256 results

Ruxolitinib for Cancer Cachexia
https://clinicaltrials.gov/ct2/show/NCT04906746

Jan 11th, 2022 - Lung cancer patients on a whole, and a significant percentage of NSCLC patients in particular, develop cancer cachexia. In fact, approximately 30-40% of all NSCLC patients will develop cachexia in their disease course, with the highest percentages...

Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes
https://clinicaltrials.gov/ct2/show/NCT02912208

Dec 29th, 2021 - Myelodysplastic syndromes (MDS) prevail in older age and are characterized by ineffective erythropoiesis and peripheral cytopenias. Supportive therapy is the main therapeutic option for most patients. Quality of Life (QoL) is mainly deteriorated b...

Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies
https://clinicaltrials.gov/ct2/show/NCT04710212

Dec 15th, 2021 - This is a prospective, observational cohort study to assess the frequency with which neutropenic patients with hematologic malignancies and hematopoietic cell transplant (HCT) recipients are colonized with fluoroquinolone-resistant Enterobacterale...

mNGS Versus Blood Culture in FN
https://clinicaltrials.gov/ct2/show/NCT05149547

Dec 8th, 2021 - Blood stream infection (BSI) during febrile neutropenia (FN) is a lethal complication, while confirmed diagnosis via blood culture is usually with low sensitivity and time delay. The new technique of metagenome next generation sequencing (mNGS) ha...

Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia
https://clinicaltrials.gov/ct2/show/NCT04948463

Dec 7th, 2021 - Febrile neutropenia (FN) is a common complication of childhood cancer treatment and a leading cause of hospital admission and antibiotic exposure. Management typically involves broad-spectrum antibiotics until resolution of fever and absolute neut...

see more →

News  1,645 results

Rapid Readout: Pirtobrutinib, A Highly Selective, Noncovalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study
https://www.onclive.com/view/pirtobrutinib-a-highly-selective-non-covalent-reversible-btk-inhibitor-in-previously-treated-cll-sll-updated-results-from-the-phase-1-2-bruin-study

Jan 14th, 2022 - Anthony Mato, MD, discusses data from the following presentation: Updated results from the phase 1/2 BRUIN study of the noncovalent BTK inhibitor (BTKi) pirtobrutinib in patients with previously treated chronic lymphocytic leukemia/small lymphocy...

Zanubrutinib Improves PFS in Treatment-Naïve CLL/SLL
https://www.onclive.com/view/zanubrutinib-improves-pfs-in-treatment-na-ve-cll-sll

Jan 14th, 2022 - Zanubrutinib (Brukinsa) elicited a statistically significant improvement in progression-free survival (PFS) vs the combination of bendamustine and rituximab (Rituxan; BR) in patients with treatment-naïve chronic lymphocytic leukemia (CLL) and smal...

Ibrutinib/Rituximab Combo Represents Effective Chemo-Free Option for Elderly Patients with MCL
https://www.onclive.com/view/ibrutinib-rituximab-combo-represents-effective-chemo-free-option-for-elderly-patients-with-mcl

Jan 14th, 2022 - The combination of ibrutinib (Imbruvica) and rituximab (Rituxan) produced a high overall response rate (ORR) and durable survival in elderly patients with mantle cell lymphoma (MCL), according to data from a phase 2 ENRICH trial (NCT0180567) publi...

Aspacytarabine Shows Efficacy, Safety in Newly Diagnosed AML Unfit for Intensive Therapy
https://www.onclive.com/view/aspacytarabine-shows-efficacy-safety-in-newly-diagnosed-aml-unfit-for-intensive-therapy

Jan 10th, 2022 - The novel antimetabolite aspacytarabine (BST-236) was found to produce a complete remission (CR) rate of 37% in adult patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive therapy, according to data from a phase 2b...

Dr. McCloskey on the Utility of Decitabine Plus Cedazuridine in Lower-Risk MDS
https://www.onclive.com/view/dr-mccloskey-on-the-utility-of-decitabine-plus-cedazuridine-in-lower-risk-mds

Jan 7th, 2022 - James K. McCloskey, MD, chief, Leukemia Division, John Theurer Cancer Center, Hackensack Meridian Health, discusses the utility of decitabine plus cedazuridine (Inqovi) in lower-risk myelodysplastic syndromes (MDS), based on data from the long-ter...

see more →

Patient Education  2 results see all →